Document Detail


Levosimendan: a review of its use in the management of acute decompensated heart failure.
MedLine Citation:
PMID:  14636085     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
CONCLUSION: Intravenous levosimendan is an effective calcium-sensitising drug with vasodilatory and inotropic effects, and superior efficacy/tolerability to those of intravenous dobutamine in patients with acute decompensated heart failure. It may be associated with reduced mortality compared with both placebo and dobutamine. Levosimendan is generally well tolerated and may have less potential for cardiac rate/rhythm disorders than dobutamine. While evidence from well designed trials confirming the improved mortality over dobutamine and investigating haemodynamic efficacy and mortality versus other positive inotropes is required, intravenous levosimendan appears to be a useful addition to the treatment options for acute decompensated heart failure in patients with low cardiac output.
Authors:
Carmen A Innes; Antona J Wagstaff
Related Documents :
9857925 - Safety and utility of atropine addition during dobutamine stress echocardiography for t...
1577035 - Dobutamine stress echocardiography: its role in the diagnosis of coronary artery disease.
10430765 - Diagnostic and prognostic value of serial dobutamine stress echocardiography for noninv...
8450165 - Dobutamine stress echocardiography predicts surgical outcome in patients with an aortic...
11316315 - Cardiac output measurements in congenital heart disease: validation of a simple, portab...
8237835 - Secondary prevention after myocardial infarction with class iii antiarrhythmic drugs.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drugs     Volume:  63     ISSN:  0012-6667     ISO Abbreviation:  Drugs     Publication Date:  2003  
Date Detail:
Created Date:  2003-11-25     Completed Date:  2004-04-29     Revised Date:  2013-05-20    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  2651-71     Citation Subset:  IM    
Affiliation:
Adis International Limited, Auckland, New Zealand.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Animals
Cardiotonic Agents / pharmacokinetics,  pharmacology,  therapeutic use*
Heart Failure / drug therapy*
Hemodynamics / drug effects
Humans
Hydrazones / pharmacokinetics,  pharmacology,  therapeutic use*
Pyridazines / pharmacokinetics,  pharmacology,  therapeutic use*
Randomized Controlled Trials as Topic
Chemical
Reg. No./Substance:
0/Cardiotonic Agents; 0/Hydrazones; 0/Pyridazines; 349552KRHK/simendan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Combined hepatitis A and B vaccines: a review of their immunogenicity and tolerability.
Next Document:  Vardenafil: a review of its use in erectile dysfunction.